

**Form 603**

Corporations Act 2001

Section 671B

**Notice of initial substantial holder**To Company Name/Scheme **Firebrick Pharma Limited**ACN/ARSN **157 765 896****1. Details of substantial holder (1)**Name **Biotech Design Pty Ltd / Stephen Francis Goodall**ACN/ARSN (if applicable) **097 086 701**

The holder became a substantial holder on

As a founder of Firebrick Pharma, Stephen has always been a substantial holder but was first required to lodge as a result of the issue of ordinary shares (Shares) in Firebrick that completed on 18 January 2022 as described in the prospectus lodged by Firebrick with ASIC on 26 November 2021 (Prospectus). This notice describes the voting power and relevant interests of the substantial holder as at 18/01/2022

**2. Details of voting power**

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:

Class of securities (4)	Number of securities	Person's votes (5)	Voting power (6)
<b>Ordinary Shares</b>	<b>30,326,472</b>	<b>30,326,472</b>	<b>17.96%</b>

**3. Details of relevant interests**

The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

Holder of relevant interest	Nature of relevant interest (7)	Class and number of securities
<b>Stephen Francis Goodall</b>	<b>Stephen Goodall has a relevant interest under sections 608(3)(a) and (b) because he has voting power of 100% in Biotech Design Pty Ltd and controls Biotech Design Pty Ltd.</b>	<b>Ordinary shares - 30,326,472</b>
<b>Biotech Design Pty Ltd</b>	<b>Biotech Design Pty Ltd has a relevant interest in the Firebrick Shares under section 608(1) as it is the registered holder of the shares.</b>	<b>Ordinary shares - 30,326,472</b>

**4. Details of present registered holders**

The persons registered as holders of the securities referred to in paragraph 3 above are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Class and number of securities
<b>Stephen Francis Goodall</b>	<b>Biotech Design Pty Ltd</b>	<b>Biotech Design Pty Ltd</b>	<b>Ordinary shares - 30,326,472</b>
<b>Biotech Design Pty Ltd</b>	<b>Biotech Design Pty Ltd</b>	<b>Biotech Design Pty Ltd</b>	<b>Ordinary shares - 30,326,472</b>

## 5. Consideration

The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:

Holder of relevant interest	Date of acquisition	Consideration (9)		Class and number of securities
		Cash	Non-cash	
Stephen Francis Goodall	12 April 2012		Founder	Ordinary shares - 30,000,000
Stephen Francis Goodall	28 July 2020	\$27,206.00		Ordinary shares - 163,236
Stephen Francis Goodall	25 October 2021	\$27,206.00		Ordinary shares - 163,236

## 6. Associates

The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
Biotech Design Pty Ltd (A.C.N. 097 086 701)	Biotech Design and Stephen Goodall are associates because Stephen Goodall is the sole director and holder of 100% of the shares of Biotech Design and the parties act in concert in relation to the affairs of Firebrick. As an incident of his sole directorship and ownership, Stephen Goodall controls Biotech Design through his practical influence over the financial and operating policies of the company.


## 7. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Biotech Design Pty Ltd	413A Orange Grove Road BLACKWALL NSW 2256
Stephen Francis Goodall	413A Orange Grove Road BLACKWALL NSW 2256

## Signature

print name      Stephen Goodall      capacity      Director and COO

sign here            date      21      / 01      / 2022

## DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 7 of the form.
- (2) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (4) The voting shares of a company constitute one class unless divided into separate classes.
- (5) The total number of votes attached to all the voting shares in the company or voting interests in the scheme (if any) that the person or an associate has a relevant interest in.
- (6) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
- (7) Include details of:
  - (a) any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection 671B(4) applies, a copy of

any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and

- (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.

- (8) If the substantial holder is unable to determine the identity of the person ( eg. if the relevant interest arises because of an option) write "unknown".
  - (9) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
-